World Investment Advisors LLC Makes New $3.46 Million Investment in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

World Investment Advisors LLC bought a new stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 43,539 shares of the company’s stock, valued at approximately $3,459,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Farther Finance Advisors LLC increased its position in Dr. Reddy’s Laboratories by 43.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock valued at $36,000 after buying an additional 137 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Dr. Reddy’s Laboratories during the third quarter valued at $60,000. Van ECK Associates Corp raised its position in shares of Dr. Reddy’s Laboratories by 64.3% in the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after purchasing an additional 322 shares during the last quarter. GAMMA Investing LLC boosted its stake in Dr. Reddy’s Laboratories by 83.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,447 shares of the company’s stock worth $115,000 after purchasing an additional 657 shares in the last quarter. Finally, Glenmede Trust Co. NA purchased a new stake in Dr. Reddy’s Laboratories during the 3rd quarter valued at about $207,000. 3.85% of the stock is owned by institutional investors.

Dr. Reddy’s Laboratories Price Performance

NYSE RDY opened at $14.46 on Friday. Dr. Reddy’s Laboratories Limited has a one year low of $13.26 and a one year high of $16.89. The stock has a 50-day moving average of $14.88 and a 200 day moving average of $15.36. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.36 and a current ratio of 1.92. The company has a market capitalization of $12.07 billion, a price-to-earnings ratio of 23.10 and a beta of 0.53.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RDY. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Barclays lowered their price objective on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.